This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
What Lies Ahead of IDEXX Laboratories (IDXX) in Q1 Earnings?
by Zacks Equity Research
IDEXX Laboratories' (IDXX) first-quarter 2024 results are likely to reflect the benefits of strong execution against the growth strategy.
TMO vs. IDXX: Which Stock Is the Better Value Option?
by Zacks Equity Research
TMO vs. IDXX: Which Stock Is the Better Value Option?
Idexx Laboratories (IDXX) Beats Stock Market Upswing: What Investors Need to Know
by Zacks Equity Research
Idexx Laboratories (IDXX) concluded the recent trading session at $519.81, signifying a +0.99% move from its prior day's close.
Elevance Health (ELV) Brand Inks Deal to Better Serve Georgia
by Zacks Equity Research
Elevance Health's (ELV) brand, Anthem Blue Cross and Blue Shield, collaborates to make the benefits of Piedmont's healthcare network available to its members across specific Georgia regions.
All You Need to Know About Idexx (IDXX) Rating Upgrade to Buy
by Zacks Equity Research
Idexx (IDXX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Will Idexx (IDXX) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Idexx (IDXX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Here's Why You Should Invest in IDEXX (IDXX) Stock Right Now
by Zacks Equity Research
The strength of the CAG Diagnostics business buoys optimism for IDEXX (IDXX).
Top Research Reports for Lam Research, PayPal & Trane
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Lam Research Corporation (LRCX), PayPal Holdings, Inc. (PYPL) and Trane Technologies plc (TT).
Idexx (IDXX) Down 1.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
IDEXX (IDXX) Unveils Pet Owner Engagement Software Solution
by Zacks Equity Research
IDEXX's (IDXX) Vello software is an intuitive solution designed specifically for practice management software that enables practitioners to interact with pet owners before and after visits.
Here's Why You Should Retain IDEXX (IDXX) Stock for Now
by Zacks Equity Research
Investors are optimistic about IDEXX (IDXX) growth in CAG business and strong global performance
IDEXX's (IDXX) Global Growth Continues, Currency Woes Persist
by Zacks Equity Research
A key element of IDEXX's (IDXX) customer engagement strategy is the expansion of its commercial footprint in a disciplined approach.
Company News for Feb 6, 2024
by Zacks Equity Research
Companies In The News Are: ON, TSN, IDXX, APD.
IDEXX (IDXX) Q4 Earnings Surpass Estimates, Margins Fall
by Zacks Equity Research
Across testing modalities, IDEXX (IDXX) achieves strong global growth in the fourth quarter.
Idexx (IDXX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Idexx (IDXX) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Idexx Laboratories (IDXX) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Idexx (IDXX) delivered earnings and revenue surprises of 9.43% and 1.45%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy IDEXX Laboratories (IDXX) Ahead of Earnings?
by Zacks Equity Research
IDEXX Laboratories (IDXX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
IQV or IDXX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
IQV vs. IDXX: Which Stock Is the Better Value Option?
Steris (STE) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Steris (STE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Unveiling Idexx (IDXX) Q4 Outlook: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of Idexx (IDXX) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Here's Why You Should Invest in IDEXX (IDXX) Stock Right Now
by Zacks Equity Research
Investors continue to be optimistic about IDEXX (IDXX), backed by the strength of the CAG Diagnostics business.
Why Idexx (IDXX) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Idexx (IDXX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
IDEXX Laboratories (IDXX) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Strength in CAG Diagnostics and Water businesses are likely to have boosted IDEXX Laboratories' (IDXX) revenues in Q4.